T1	MajorClaim 1 143	For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
T2	Premise 1092 1261	DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).
T3	Premise 1262 1359	Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,
T4	Premise 1408 1495	Pain-free survival and time to first cancer pain-related opioid intake were comparable.
T5	Claim 1663 1830	The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.
T6	Premise 1360 1407	the results were not statistically significant.
R1	Support Arg1:T4 Arg2:T5
R2	Attack Arg1:T6 Arg2:T3
R3	Support Arg1:T2 Arg2:T5
R4	Partial-Attack Arg1:T3 Arg2:T2
